KCCOP Protocol Summary

 Home | Print Summary

The summary below serves as a brief review of the treatment plan and eligibility for the protocol.
This summary is not intended to be used in place of the full protocol.
Members may follow the "Full Protocol" link or contact KCCOP for complete protocol information.

 

 Full Protocol

(members only)

 

Consent Form

 

HIPAA

 

Spanish Consent Form

RTOG 0627 - "Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme"

 

Treatment Plan    (Supplied Drug:  Dasatinib)

 

Dasatinib:  100mg, PO, BID

Continue q 28 days until disease progression or adverse events.

 

Eligibility